SCHEMBL6353239

SCHEMBL6353239

O=C1Nc2ccccc2C1=C1C=Cc2cc(CN3CCN(C4CCCCC4)CC3)ccc2N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
TSHR P16473 3/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
TRPV6 Q9H1D0 2/20 0.38
HRH3 Q9Y5N1 1/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
ALOX12 P18054 1/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6353236 1.00 MEN1 (0.43) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL6353004 0.84 ALDH1A1 (0.38) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL6350535 0.84 PRKCB (0.42) MEN1KMT2AALDH1A1KDM4EHTT
SCHEMBL6350539 0.84 PRKCB (0.42) MEN1KMT2AALDH1A1KDM4EHTT
SCHEMBL6353001 0.84 ALDH1A1 (0.38) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL6355402 0.75 NTRK1 (0.38) ALDH1A1KDM4EMAPK1HTTMAPT
SCHEMBL6355403 0.75 NTRK1 (0.38) ALDH1A1KDM4EMAPK1HTTMAPT
SCHEMBL6360178 0.71 PDCD1 (0.41) OPRM1OPRK1
SCHEMBL6360180 0.71 PDCD1 (0.41) OPRM1OPRK1
SCHEMBL6434497 0.70 TNKS2 (0.44) MEN1KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-04-28 US disclosed
EP-1396490-A1 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative KDR, FLT4, FLT1 MEN1 2955/4885KMT2A 2370/4885ALDH1A1 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.